Related Experiment Video
Updated: Jul 7, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Prasugrel, a third generation thienopyridine and potent platelet inhibitor
Paul A Gurbel1, Udaya S Tantry
1Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org
Current Opinion in Investigational Drugs (London, England : 2000)
|March 4, 2008
Summary
Prasugrel, a novel antiplatelet medication, is nearing US approval for preventing blood clots in stroke and heart attack patients. This third-generation thienopyridine derivative shows promise in treating thromboembolism.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Thromboembolic events remain a significant cause of morbidity and mortality, particularly in patients with ischemic strokes and acute coronary syndromes.
- Existing antiplatelet therapies have limitations, necessitating the development of more effective agents.
- Thienopyridine derivatives represent a class of drugs with potent antiplatelet activity.
Purpose of the Study:
- To evaluate the efficacy and safety of prasugrel, a novel thienopyridine derivative, for the prevention of thromboembolism.
- To assess the potential of prasugrel as a treatment option for patients experiencing ischemic strokes or acute coronary syndromes.
Main Methods:
- Prasugrel is a third-generation thienopyridine derivative currently undergoing Phase III clinical trials.
- Development is being conducted by Eli Lilly & Co and Daiichi Sankyo Co Ltd.
- The drug is being investigated for its therapeutic potential in managing thromboembolic conditions.
Main Results:
- Prasugrel has successfully completed Phase III clinical trials in Western Europe and Japan.
- The drug has demonstrated efficacy in preclinical and clinical studies for preventing blood clot formation.
- Regulatory approval is pending in the United States.
Conclusions:
- Prasugrel is poised to become a valuable therapeutic option for patients at risk of thromboembolic events.
- The drug's anticipated launch in the US by the end of 2008 signifies a potential advancement in cardiovascular pharmacotherapy.
- Further post-marketing surveillance will be crucial to fully understand its long-term impact.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...